CNS Drug Reviews

نویسندگان

  • Jennifer Altman
  • Richard Mayeux
  • Yves Christen
چکیده

In the next 50 years, Alzheimer’s disease (AD) is likely to become one of the world’s largest public health problems, second only to cancer, unless ways of preventing the disease or treating its preclinical stages are found. Prevention requires the early identification of likely sufferers and determination of the risks that predispose them to AD, information that comes only from large-scale and long-term studies of populations. The progress made in such epidemiological studies and the questions that remain to be answered were the topic of this year’s colloquium on Alzheimer’s disease, organized for Foundation IPSEN by Richard Mayeux (Columbia Univ., New York) and Yves Christen (Foundation IPSEN, Paris) and held in Paris on May 25, 1998. Unlike most of the IPSEN Alzheimer’s colloquia, which concentrate on the details of the disease mechanism, the focus of this discussion was the people who have or may develop AD and other dementias. Because of the problems of establishing a clear diagnosis of AD during life, much of the discussion dealt with dementia rather than specifically with AD, although most speakers considered about 80% of the cases in their samples to be AD. Population studies are essential for determining how best to provide for and treat sufferers in the future, but are also providing valuable pointers to the causes of dementia and in some cases even to potential treatments. Results are now available from several large long-term studies of populations in the USA and Europe, as well as some smaller comparisons of groups with different ethnic or cultural backgrounds. Although these studies are not directly comparable because of differing designs and criteria, they point inescapably to a large increase in the number of people with the disease as the population ages. As important as it is to observe who has the disease (prevalence) and who is getting it (incidence), the work has now moved into a more sophisticated analytical phase (Mayeux), revealing indicators of early disease, and genetic and environmental risk and protective factors. Perhaps more significant in the long term, the ground is being prepared for the time when preventive measures become available by opening up a debate on both the practical and ethical issues surCNS Drug Reviews Vol. 4, No. 2, pp. 196–200 © 1998 Neva Press, Branford, Connecticut

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Targeted drug delivery to treat pain and cerebral hypoxia.

Limited drug penetration is an obstacle that is often encountered in treatment of central nervous system (CNS) diseases including pain and cerebral hypoxia. Over the past several years, biochemical characteristics of the brain (i.e., tight junction protein complexes at brain barrier sites, expression of influx and efflux transporters) have been shown to be directly involved in determining CNS p...

متن کامل

Hu 210: a potent tool for investigations of the cannabinoid system.

The synthetic compound HU 210 displays a multiplicity of biochemical, pharmacological, and behavioral effects, most of which have been demonstrated to be dependent on a selective agonistic activity at CB(1) and CB(2) cannabinoid receptors and to involve the main neurotransmitter systems. Results obtained in various studies suggest a potential clinical application of this highly potent drug (e.g...

متن کامل

Regulation of the NMDA receptor: implications for neuropsychological development.

Recent work has shown that zinc is involved in the developmental regulation of neurotrophins and N-methyl-D-aspartate (NMDA) receptors, controlling use of glutamate as a neurotransmitter in the central nervous system (CNS). This is particularly important in the hippocampus, a region of the brain involved in learning and memory, and is an intriguing link to the role of zinc in neuropsychological...

متن کامل

Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.

Dextromethorphan (DM) is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, which is widely used as an antitussive agent. DM also prevents neuronal damage and modulates pain sensation via noncompetitive antagonism of excitatory amino acids (EAAs). DM has been found to be useful in the treatment of pain in cancer patients and in the treatment of methotrexate-induced neurotoxicity....

متن کامل

Approaches to neural tissue engineering using scaffolds for drug delivery.

This review seeks to give an overview of the current approaches to drug delivery from scaffolds for neural tissue engineering applications. The challenges presented by attempting to replicate the three types of nervous tissue (brain, spinal cord, and peripheral nerve) are summarized. Potential scaffold materials (both synthetic and natural) and target drugs are discussed with the benefits and d...

متن کامل

Biomaterials for the central nervous system.

Biomaterials are widely used to help treat neurological disorders and/or improve functional recovery in the central nervous system (CNS). This article reviews the application of biomaterials in (i) shunting systems for hydrocephalus, (ii) cortical neural prosthetics, (iii) drug delivery in the CNS, (iv) hydrogel scaffolds for CNS repair, and (v) neural stem cell encapsulation for neurotrauma. T...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 1999